NCCS - For Researchers

HELP DESK : +65 6436 8000 CANCER HELPLINE : +65 6225 5655

Home | Contact Us | Join Us | Sitemap

About Us News Room Events Cancer Information Publications Tenders Useful Links

Overview

Institutional Review Board (IRB) Submission

Research Programmes

Research Collaborators

Research News

Research Publications

Research Awards

Home > For Researchers > Research Publications

Research Publications

Year
1.	Heindl M, Händel N, Ngeow J, Kionke J, Wittekind C, Kamprad M, Rensing-Ehl A, Ehl S, Reifenberger J, Loddenkemper C, Maul J, Hoffmeister A, Aretz S, Kiess W, Eng C, Uhlig HH(2012) Autoimmunity, intestinal lymphoid hyperplasia, and Defects in Mucosal B-Cell Homeostasis in Patients with PTEN Hamartoma Tumor Syndrome. Gastroenterology 2012 Jan 19 : Epub ahead of print (Impact factor:12.032)
2.	Kadakia MP, de-Fromentel CC, Sabapathy K(2012) The 5th International p63/p73 workshop: much more than just tumour suppression. Cell Death Differ 2012 Jan 13. doi: 10.1038/cdd.2011.204 : Epub ahead of print (Impact factor:9.050)
3.	Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C(2012) Lifetime Cancer Risks in Individuals with Germline PTEN Mutations. Clin Cancer Res 18(2) : 400-407 (Impact factor:7.338)
4.	Teo CR, Law HY, Lee CG, Chong SS(2012) Fragile X Mental Retardation 1 Gene CGG Repeat Expansion Screening by Melting Curve Analysis of Combined 5' and 3' Direct Triplet-Primed PCRs. Clin Chem 2012 Jan 5 : Epub ahead of print (Impact factor:6.886)
5.	Manegold C, van Zandwijk N, Szczesna A, Zatloukal P, Au JS, Blasinska-Morawiec M, Serwatowski P, Krzakowski M, Jassem J, Tan EH, Benner RJ, Ingrosso A, Meech SJ, Readett D, Thatcher N(2012) A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol 23(1) : 72-77 (Impact factor:6.452)
6.	Ng QS, Mandeville H, Goh V, Alonzi R, Milner J, Carnell D, Meer K, Padhani AR, Saunders MI, Hoskin PJ(2012) Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck. Ann Oncol 23(1) : 231-237 (Impact factor:6.452)
7.	Kho KW, Shen Z, Olivo M(2012) Generation of Ultralarge Surface Enhanced Raman Spectroscopy (SERS)-Active Hot-Spot Volumes by an Array of 2D Nano-Superlenses. Anal Chem 84(2) : 908-916 (Impact factor:5.874)
8.	U S D, Fu CY, Soh KS, Ramaswamy B, Kumar A, Olivo M(2012) Highly sensitive SERS detection of cancer proteins in low sample volume using hollow core photonic crystal fiber. Biosens Bioelectron 2012 Jan 4 : Epub ahead of print (Impact factor:5.361)
9.	Ciuffreda L, Di Sanza C, Cesta Incani U, Eramo A, Desideri M, Biagioni F, Passeri D, Falcone I, Sette G, Bergamo P, Anichini A, Sabapathy K, McCubrey JA, Ricciardi MR, Tafuri A, Blandino G, Orlandi A, De Maria R, Cognetti F, Del Bufalo D, Milella M(2012) The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. J Mol Med (Berl) 2012 Jan 4 : Epub ahead of print (Impact factor:5.192)
10.	Tan MH, De S, Bebek G, Orloff MS, Wesolowski R, Downs-Kelly E, Budd GT, Stark GR, Eng C(2012) Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer. Breast Cancer Res Treat 131(3) : 849-858 (Impact factor:4.859)
11.	Ng R, Lee CF, Wong NS, Luo N, Yap YS, Lo SK, Chia WK, Yee A, Krishna L, Goh C, Cheung YB(2012) Measurement properties of the English and Chinese versions of the Functional Assessment of Cancer Therapy-Breast (FACT-B) in Asian breast cancer patients. Breast Cancer Res Treat 131(2) : 619-625 (Impact factor:4.859)
12.	Ng T, Chan A(2012) Dosing modifications of targeted cancer therapies in patients with special needs: Evidence and controversies. Crit Rev Oncol Hematol 81(1) : 58-74 (Impact factor:4.689)
13.	Ng QS, Thng CH, Lim WT, Hartono S, Thian YL, Lee PS, Tan DS, Tan EH, Koh TS(2012) Dynamic contrast-enhanced computed tomography in metastatic nasopharyngeal carcinoma: reproducibility analysis and observer variability of the distributed parameter model. Invest Radiol 47(1) : 5-10 (Impact factor:4.665)
14.	Goh V, Ng QS, Miles K(2012) Computed tomography perfusion imaging for therapeutic assessment: has it come of age as a biomarker in oncology?. Invest Radiol 47(1) : 2-4 (Impact factor:4.665)
15.	Tan LH, Tan SY, Tang T, Lim ST, Tan D, Lim LC, Kam GL, Loh TP, Tao M, Koay ES(2012) Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centres (pattern 1) shows superior survival to patterns 2 and 3: a meta-analysis of 56 cases. Histopathology 2012 Jan 17. doi: 10.1111/j.1365-2559.2011.04097.x : Epub ahead of print (Impact factor:3.569)
16.	Chan A, Rong De Ng T, Yi-Lwern Yap K(2012) Clinically-relevant anticancer-antidepressant drug interactions. Expert Opin Drug Metab Toxicol 8(2) : 173-199 (Impact factor:3.374)
17.	Wong FY, Yip CS, Chua ET(2012) Implications of HER2 Amplification in Small, Node-Negative Breast Cancers: Do Asians Differ?. World J Surg 36(2) : 287-294 (Impact factor:2.693)
18.	Tan PH, Thike AA, Tan WJ, Thu MM, Busmanis I, Li H, Chay WY, Tan MH, The Phyllodes Tumour Network Singapore(2012) Predicting clinical behaviour of breast phyllodes tumours: a nomogram based on histological criteria and surgical margins. J Clin Pathol 65(1) : 69-76 (Impact factor:2.475)
19.	Yang Y, Goh SY, Tan SB, Ho HJ, Emmanuel S, Wang P, Ng HS(2012) The burden of diabetes mellitus in elderly patients from an Asian tertiary hospital. Eur J Intern Med 23(1) : e1-e4 (Impact factor:1.657)
20.	Krishna L, Poulose VJ, Goh C(2012) The use of midazolam and haloperidol in cancer patients at the end of life. Singapore Med J 53(1) : 62-66 (Impact factor:0.730)

Disclaimer | Privacy | Terms of Use